Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates Losatuxizumab vedotin and Depatux-M in glioblastoma models.
Sonia JainJessica I GriffithKendra A PorathSneha RathiJiayan LeTugce I PasaPaul A DeckerShiv K GuptaZeng HuBrett L CarlsonKatrina K BakkenDanielle M BurgenskeThomas M FeldsienDidier R LefebvreRachael Ann VaubelJeanette E Eckel-PassowEdward B ReillyWilliam F ElmquistJann N SarkariaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
EGFR-targeting ADCs are promising therapeutic options for GBM when delivered intra-tumorally by CED. However, the linker and payload for the ADC must be carefully considered to maximize the therapeutic window.